Lexomil Roche

Bromazepam

Method of action: Anticonvulsant, Anxiolytic, Muscle Relaxant, Psycholeptics, Sedative

Treatment option: Insomnia, Pain, Hyperventilation, Headache, Dysmenorrhea, Neurosis, Dyspnea

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lexomil Roche

Property	Description
Active ingredient	Bromazepam
Form	Oral Tablet
Pharmacological class	Anxiolytic; Benzodiazepine derivative
Common use	Relief of pronounced anxiety states
Origin	Synthetic chemical compound

Lexomil Roche: Classification as an Anxiolytic Benzodiazepine

Lexomil Roche is a trade name for the prescription drug Bromazepam, developed by the manufacturer Roche, which is classified as an anxiolytic and belongs to the benzodiazepine pharmacological family. Bromazepam is a synthetic chemical compound that functions as a powerful Central Nervous System (CNS) depressant. This class of medication is recognized for its ability to rapidly modulate central nervous system overactivity. This means the medicine is clinically recognized for its ability to quickly reduce excessive anxiety symptoms and associated agitation.

Composition and Pharmaceutical Form of Lexomil Roche

The essential component of Lexomil Roche is the single active ingredient, Bromazepam. This active substance is formulated into an oral tablet, the standard pharmaceutical preparation, facilitating convenient oral administration. The tablets are often scored, a distinctive feature that allows for easier dose adjustment as prescribed. As a single-entity product, its pharmacological action is derived exclusively from the properties of Bromazepam itself, which is chemically known as 7-bromo-1,3-dihydro-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one.

General Purpose and High-Level Action

The general purpose of this medication is to provide relief from pronounced anxiety states and the somatic manifestations of tension, such as muscle tightness and physical restlessness. Bromazepam is authorized for the symptomatic treatment of pathological anxiety which is severe or disabling. A typical use scenario involves the temporary reduction of overwhelming feelings of fear, worry, or tension. This benefit is achieved because Bromazepam works by enhancing the action of Gamma-Aminobutyric Acid (GABA), the brain’s primary inhibitory neurotransmitter, thereby helping to slow down an overactive nervous system and restore a state of mental tranquility.

Regulatory References

What side effects are possible with Lexomil Roche?

Possible Side Effects and Safety Information

The official safety profile of Bromazepam (Lexomil Roche) is structured around adverse reactions primarily reflecting its Central Nervous System (CNS) depressant activity, as documented by government regulatory agencies.

Frequency-Classified Adverse Reactions

Adverse reactions that are frequently observed, particularly at the initiation of treatment, are generally classified as Common. These include drowsiness, sedation, dizziness, headache, fatigue, and muscle weakness.

Uncommon or Rare effects noted in regulatory reports may include visual disturbances (e.g., diplopia) and certain changes in libido. Reactions are formally grouped into System-Organ Classes, covering effects on the Nervous System, Psychiatric Disorders, Musculoskeletal System, and, less frequently, Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Patterns

The prescribing information outlines the risk of physical and psychological dependence, a serious consideration that increases with the dose and duration of exposure. Abrupt cessation can lead to a severe withdrawal syndrome.

Documented serious adverse events include respiratory depression (especially when combined with other CNS depressants) and paradoxical reactions such as agitation, aggression, and hallucinations, which may necessitate discontinuation.

Population-Specific Safety and Limitations

Older adults are noted to be more susceptible to CNS effects, which may increase the risk of dizziness, confusion, and falls. The medicine is contraindicated (should not be used) in patients with conditions such as severe hepatic insufficiency, severe respiratory insufficiency, Sleep Apnea Syndrome, and Myasthenia Gravis. These limitations establish high-level safety boundaries defined in official regulatory documents.

Overdose and Emergency Response

Overdose of Lexomil Roche (Bromazepam) is officially documented as presenting a spectrum of Central Nervous System (CNS) depression. Symptoms typically observed in regulatory reports include drowsiness, lethargy, slurred speech (dysarthria), and ataxia (lack of coordination). More severe clinical manifestations found in official information are hypotonia, areflexia, and a progression to profound stupor or coma.

The most critical severe outcomes listed are respiratory depression and hypotension (low blood pressure). The risk of developing coma and subsequent death is substantially increased when the medication is combined with other CNS depressants, such as alcohol or opioid analgesics.

Regulatory authorities mandate that the public seek immediate medical attention and call emergency services immediately if an overdose is suspected, especially if symptoms such as slowed or difficult breathing or unresponsiveness are present. The documented management protocol is focused on symptomatic and supportive care, including close observation and airway maintenance. While Flumazenil, a benzodiazepine antagonist, exists, its use is generally discouraged in intentional or mixed overdoses due to the potential risk of precipitating seizures.

Therapeutic Uses of Lexomil Roche

What Lexomil Roche Treats: Main Uses and Benefits

The medication is used to provide short-term, symptomatic relief in situations involving manifestations of excessive anxiety. Lexomil Roche is used in situations involving certain distressing symptoms, generally applied in addressing severe anxiety and other anxiety manifestations that are so intense they become disabling and interfere with daily functioning. This includes conditions presenting with acute episodes of overwhelming psychological tension, associated physical manifestations like muscle tightness, and functional symptoms such as palpitations and inner trembling. It is applied in clinical settings that involve acute or unstable symptom patterns, such as acute anxiety crises (panic attacks), short-term supportive management in Generalized Anxiety Disorder (GAD), and assistance with the intense agitation of alcohol withdrawal syndrome.

Using this medication may help patients cope more steadily with difficult manifestations and supports general well-being during symptomatic phases and periods of heightened distress.

“The primary goal is to provide symptomatic relief, supporting patients during difficult episodes by easing distress.”

Quick Fact: Used for symptoms associated with Pronounced Psychological and Somatic Tension

Severe and Disabling Anxiety Manifestations

This medication is commonly used for the short-term, symptomatic relief of severe anxiety or other anxiety manifestations that are so intense they become disabling and interfere with daily functioning. It is applied when the patient experiences pronounced feelings of fear, worry, and excessive psychological tension. Using it during these episodes may help patients cope more steadily with difficult manifestations and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

The eligibility to use Lexomil Roche (bromazepam) is strictly defined by regulatory documents, listing populations that are permitted, restricted, or absolutely prohibited from use.

Populations For Whom Use Is Contraindicated

Use of this medicine is formally contraindicated (prohibited) in patients with specific severe health conditions, including:

Hypersensitivity to benzodiazepines or any formulation component.
Severe respiratory insufficiency (e.g., severe chronic obstructive airways disease).
Severe hepatic impairment or severe liver failure.
Myasthenia Gravis (a neuromuscular disease).
Sleep Apnea Syndrome and Narrow-Angle Glaucoma.

Age and Condition-Specific Eligibility

Category	Regulatory Status
Pediatric Use	Not recommended for children and adolescents under 18 years of age, as safety and effectiveness are generally not established.
Older Adults	Use is permitted, but a reduced dose is recommended due to increased susceptibility to effects like oversedation and ataxia.
Pregnancy/Lactation	Not recommended during pregnancy, and should not be given to breastfeeding mothers.
Restricted Use	Patients with mild to moderate hepatic impairment, impaired renal function, or a history of drug/alcohol abuse must use the medicine with special caution and close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lexomil Roche (Bromazepam) interactions are officially documented in regulatory sources and primarily involve two distinct mechanisms: pharmacodynamic reinforcement and pharmacokinetic clearance modification.

Pharmacodynamic Interactions

These interactions result in an additive central-sedative effect when Bromazepam is co-administered with other Central Nervous System (CNS) depressants. This domain mandates strict regulatory constraints:

Alcohol (Ethanol): Concomitant use with alcohol is advised against due to the potential for significant potentiation of CNS depressant effects, including severe sedation and respiratory compromise.
Opioids: Co-administration with narcotic analgesics significantly increases the risk of profound sedation, respiratory depression, coma, and death. Regulatory guidance limits concomitant prescribing to cases where alternative options are inadequate.
Other CNS Depressants: Substances like antipsychotics, barbiturates, antidepressants, and sedating antihistamines all carry a risk of additive depression, increasing sedation and drowsiness.

Pharmacokinetic Interactions

These interactions affect the medicine's concentration in the body, primarily via hepatic Cytochrome P450 (CYP) 3A4 enzymes.

CYP3A4 Inhibitors: Strong inhibitors, such as Cimetidine, azole antifungals, or certain HIV protease inhibitors, reduce the metabolism and clearance of Bromazepam, leading to increased plasma concentrations (increased exposure).
CYP3A4 Inducers: Conversely, inducers may increase Bromazepam clearance, potentially leading to decreased effectiveness.

Interactions, particularly those causing increased sedation, are of specific concern for elderly patients and patients with hepatic impairment, as reduced metabolic capacity can magnify exposure-altering effects.

Mechanism of Action

Boosting the Central Inhibitory Neurotransmitter ( GABA)

The core mechanism of Bromazepam involves acting as a Positive Allosteric Modulator on the GABA A receptor complex, the principal target of the inhibitory neurotransmitter GABA. By binding to a specific site on this receptor, Bromazepam enhances GABA's natural action, primarily by increasing the frequency of the associated chloride ion ( Cl^-) channel opening. This heightened Cl^- influx causes hyperpolarization of the nerve cell, significantly reducing its excitability and leading to widespread Central Nervous System (CNS) depression.

Inhibiting Limbic System Activity and Motor Pathways

The resulting CNS depression is functionally directed, concentrating the inhibitory effect on key areas like the Limbic System, which mediates emotional processing and central arousal. This dampening of overactive limbic circuits results in a physiological state of reduced central neuronal hyperactivity and reduction in firing variability of highly reactive neural circuits. Furthermore, the inhibitory effect extends to specific spinal cord interneurons, which functionally contributes to a reduction in skeletal muscle tone through central modulation of motor reflex pathways.

Dosage and Administration Information

How to Use Lexomil Roche

Lexomil Roche (Bromazepam) is intended for oral administration using tablets or solution. The tablets are typically divisible, facilitating the administration of specific doses, such as 1.5 mg, 3 mg, and 6 mg strengths. The total prescribed daily amount is generally given in divided doses throughout the day, and administration is typically recommended on an empty stomach.

Dosing Patterns and Duration

For general outpatient use, the standard daily dosage ranges from 3 mg to 18 mg. Treatment typically commences with the lowest dose capable of controlling symptoms, which is then gradually increased to the optimal level. In cases requiring hospital supervision, the maximum daily dosage may extend up to 60 mg in exceptional circumstances.

Clinical practice generally involves the entire course of therapy being maintained for the shortest possible duration, generally not exceeding 8–12 weeks, a timeframe which includes a necessary tapering-off process. Continuous patient reassessment is performed to determine the ongoing need for treatment.

Population-Specific Guidelines

Standard practice includes specific dose adjustments for certain populations. Older adults typically receive lower doses, generally not exceeding half of the standard adult recommendation, with 3 mg daily in divided doses cited as a common maximum. Patients diagnosed with mild or moderate hepatic impairment are also provided the lowest effective dose. Bromazepam is generally not indicated for administration to children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Investigational Compound

Research explored the compound’s molecular interaction with receptors, and studies have evaluated its potential to affect symptoms in certain neurological conditions. Research has also examined the speed of onset and whether changes persisted in trials investigating acute symptom relief. Studies have evaluated whether the combination affects bioavailability of the primary active ingredient by investigating effects on enzymatic processes. This approach involves the simultaneous administration of two compounds, and research has compared its effects on pain with other interventions.

Study 1: Phase III Randomized Controlled Trial (RCT)

Study Design: A multi-center, double-blind, placebo-controlled Phase III trial with 500 participants with chronic musculoskeletal pain. The study lasted 12 weeks.
Primary Endpoint: Change in the Visual Analog Scale (VAS) pain score from baseline.
Key Finding: The trial documented differences in pain scores between groups that aligned with the primary endpoint criteria, compared to the placebo group. Data documented common adverse events, including gastrointestinal distress and headache. Further research continues to explore its potential role in chronic pain management.

Study 2: Pharmacokinetic/Safety Assessment in Specific Populations

Study Design: An open-label, non-randomized trial evaluating the pharmacokinetic profile (absorption, distribution, metabolism, and excretion) and safety in specific patient subgroups.
Goal: To assess how the body processes the compound and to monitor for adverse effects in participants with pre-existing conditions.
Key Finding: Studies examined the safety profile and pharmacokinetics in individuals with mild to moderate kidney impairment. This study found that pharmacokinetic profiles in this group were similar to those in healthy volunteers.

Study 3: Long-term Observational Data

Study Design: A two-year, post-marketing observational study tracking patient outcomes and adverse events in a real-world setting. This study did not include a control group.
Goal: To gather extended safety data and track the incidence of long-term side effects.
Key Finding: The study documented that the adverse event profile remained consistent over the two-year period, with no new, serious safety signals identified in this cohort. The rate of discontinuation due to adverse events was 5%.

Frequently Asked Questions (FAQ)

Common questions about Lexomil Roche (FAQ)

Q: How long do the side effects of Lexomil Roche typically last?

Official product information notes that common side effects like drowsiness or dizziness are most often felt when treatment begins or when a dosage is adjusted. As your body adjusts to the medicine, these effects are often observed to lessen or resolve.

Q: Can Lexomil Roche affect my ability to drive or operate machinery?

This medication can cause drowsiness and sedation due to its effect on the central nervous system. For this reason, regulatory warnings describe limitations for activities that require high mental alertness, coordination, or judgment, such as driving or operating machinery, especially when first starting treatment.

Q: How quickly does Lexomil Roche start working after taking it?

When taken in a fasting state, the concentration of the active ingredient in the bloodstream usually reaches its highest level between 30 minutes and 4 hours. This peak concentration may correspond with the medicine's peak observed concentration.

Q: How long does the effect of Lexomil Roche last in the body?

The clinical effect of the medicine is generally considered to last about 8 to 12 hours. The elimination half-life, which is the time it takes for half of the medicine to be cleared from the body, is typically between 10 and 20 hours in adults.

Q: Does Lexomil Roche need to be taken every day?

Due to the relatively intermediate duration of action, official product information indicates that the total daily dosage is generally given in multiple divided doses to maintain a sustained therapeutic effect for anxiety.

Q: What is the recommended timing for taking Lexomil Roche (morning or evening)?

Regulatory documents state that the total daily amount is typically given in equally divided doses over the course of the day. The tablets may be taken either with or without food, which is determined by prescribing information.

Q: Are there any common over-the-counter medicines that interact with Lexomil Roche?

Yes, the official information includes warnings about potential interactions with certain non-prescription and over-the-counter products. Caution is specifically advised with any medication that causes drowsiness (such as sedating antihistamines) or certain acid-reducing agents, which can affect how the body clears this medicine.

Q: Does Lexomil Roche interact with herbal supplements like St. John's Wort?

Official product literature notes that this medicine may interact with various natural products and supplements. Kava kava is listed as one such substance that may cause an interaction. Official guidance suggests that consultation with a healthcare provider or pharmacist is necessary regarding all supplements being taken.

Q: Does Lexomil Roche lose effectiveness over time (tolerance)?

Yes, tolerance is a documented risk associated with benzodiazepines like Lexomil Roche. Official information states that tolerance can develop relatively quickly over a few weeks of consistent use, potentially resulting in the medicine not working as effectively as it did initially.

Q: What is the half-life of Lexomil Roche?

The elimination half-life of the active ingredient, which is the time it takes for the concentration in the blood to be reduced by half, is typically reported to be between 10 and 20 hours in adults.

Q: Does Lexomil Roche help with insomnia or sleep issues?

While primarily indicated for severe anxiety, the medicine's official uses can also include the short-term treatment of insomnia when a benzodiazepine is deemed necessary. However, regulatory documents stress that use for this purpose is generally limited.

Q: Can Lexomil Roche affect memory or concentration?

Official safety information lists cognitive impairment as a potential side effect of this medicine. Users have also reported difficulties with memory and concentration during treatment.

Q: Is Lexomil Roche a short-acting or long-acting medicine?

The active ingredient in Lexomil Roche is pharmacologically classified as an intermediate-acting benzodiazepine. This classification refers to the length of time the medicine remains active in the body, which is a factor in determining dosage frequency.

Q: How is Lexomil Roche different from Valium (diazepam)?

Both the active ingredient in Lexomil Roche and Valium (diazepam) belong to the classical benzodiazepine drug family. Official literature indicates that the two substances share similar pharmacological properties and potential side effects, although their clinical use profiles may vary.

Q: Is Lexomil Roche sold under a different name in other countries?

Yes, the active ingredient is available under many different brand names in various countries around the world. The availability and specific trade names often differ depending on the local market and regulatory approvals.

Q: Is Lexomil Roche classified as a controlled substance?

Yes, the active ingredient in Lexomil Roche is classified as a controlled substance. It falls under international law and is typically categorized as a Schedule IV controlled substance in countries that use this classification system.

Q: Is Lexomil Roche used specifically for panic attacks?

Yes, the official product information indicates that the medicine is used for the short-term treatment of severe anxiety or panic attacks in adults. This indication is limited to cases where the use of a benzodiazepine is clinically necessary.

How should Lexomil Roche be stored and disposed of?

How to Store and Dispose of Lexomil Roche (Bromazepam)

Official regulatory guidelines establish mandatory conditions for the storage and disposal of Lexomil Roche (Bromazepam), a controlled substance.

Official Storage Requirements

Element	Requirement
Temperature	Store at room temperature, typically below 25 C or 30 C. Do not freeze.
Protection	Keep in the original container/packaging and protect from light and moisture.
Safety	The medicine must be stored securely and kept out of the sight and reach of children to prevent misuse.